Aster Capital Management DIFC Ltd Sells 3,735 Shares of IDEXX Laboratories, Inc. $IDXX

Aster Capital Management DIFC Ltd lowered its position in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 95.0% during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 195 shares of the company’s stock after selling 3,735 shares during the period. Aster Capital Management DIFC Ltd’s holdings in IDEXX Laboratories were worth $125,000 as of its most recent SEC filing.

Other hedge funds have also recently added to or reduced their stakes in the company. EverSource Wealth Advisors LLC lifted its holdings in shares of IDEXX Laboratories by 2.5% in the 3rd quarter. EverSource Wealth Advisors LLC now owns 621 shares of the company’s stock worth $397,000 after purchasing an additional 15 shares in the last quarter. STF Management LP increased its stake in IDEXX Laboratories by 1.3% during the 2nd quarter. STF Management LP now owns 1,240 shares of the company’s stock valued at $665,000 after purchasing an additional 16 shares in the last quarter. Clearstead Trust LLC raised its holdings in IDEXX Laboratories by 1.1% during the second quarter. Clearstead Trust LLC now owns 1,515 shares of the company’s stock worth $813,000 after buying an additional 16 shares during the last quarter. MassMutual Private Wealth & Trust FSB raised its holdings in IDEXX Laboratories by 4.4% during the third quarter. MassMutual Private Wealth & Trust FSB now owns 380 shares of the company’s stock worth $243,000 after buying an additional 16 shares during the last quarter. Finally, Moss Adams Wealth Advisors LLC lifted its stake in shares of IDEXX Laboratories by 3.3% in the third quarter. Moss Adams Wealth Advisors LLC now owns 528 shares of the company’s stock valued at $337,000 after buying an additional 17 shares in the last quarter. Institutional investors and hedge funds own 87.84% of the company’s stock.

Insider Buying and Selling at IDEXX Laboratories

In related news, EVP George Fennell sold 11,345 shares of the company’s stock in a transaction that occurred on Tuesday, February 10th. The shares were sold at an average price of $646.72, for a total transaction of $7,337,038.40. Following the sale, the executive vice president directly owned 9,823 shares in the company, valued at approximately $6,352,730.56. This represents a 53.60% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director Sophie V. Vandebroek sold 1,464 shares of IDEXX Laboratories stock in a transaction that occurred on Tuesday, February 17th. The shares were sold at an average price of $628.62, for a total transaction of $920,299.68. Following the completion of the transaction, the director owned 648 shares of the company’s stock, valued at $407,345.76. This represents a 69.32% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders have sold 20,873 shares of company stock valued at $13,408,523. 0.98% of the stock is owned by corporate insiders.

IDEXX Laboratories Trading Down 0.6%

Shares of IDXX stock opened at $656.73 on Monday. The company has a quick ratio of 0.90, a current ratio of 1.23 and a debt-to-equity ratio of 0.23. The company has a 50 day moving average of $672.95 and a 200-day moving average of $669.12. IDEXX Laboratories, Inc. has a 12-month low of $356.14 and a 12-month high of $769.98. The firm has a market cap of $52.29 billion, a P/E ratio of 50.25, a PEG ratio of 3.99 and a beta of 1.66.

IDEXX Laboratories (NASDAQ:IDXX) last announced its quarterly earnings data on Monday, February 2nd. The company reported $2.92 earnings per share for the quarter, missing the consensus estimate of $2.93 by ($0.01). The firm had revenue of $1.09 billion during the quarter, compared to analysts’ expectations of $1.07 billion. IDEXX Laboratories had a return on equity of 69.78% and a net margin of 24.62%.The company’s revenue was up 14.3% compared to the same quarter last year. During the same period last year, the business posted $2.53 EPS. IDEXX Laboratories has set its FY 2026 guidance at 14.290-14.800 EPS. Sell-side analysts anticipate that IDEXX Laboratories, Inc. will post 11.93 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on IDXX. Piper Sandler lowered their target price on shares of IDEXX Laboratories from $775.00 to $750.00 and set a “neutral” rating on the stock in a report on Monday, February 9th. Stifel Nicolaus set a $775.00 price objective on IDEXX Laboratories in a report on Monday, November 3rd. Leerink Partners set a $785.00 price objective on IDEXX Laboratories in a research note on Monday, November 3rd. Barclays cut their target price on IDEXX Laboratories from $850.00 to $800.00 and set an “overweight” rating on the stock in a research report on Thursday, February 5th. Finally, BTIG Research lowered their price target on IDEXX Laboratories from $830.00 to $800.00 and set a “buy” rating for the company in a research report on Tuesday, February 3rd. Seven investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $783.33.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.